Trial · NCT02871778
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: VX-371 in HS | Participants with TEAEs | 52 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: HS | Participants with TEAEs | 46 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: VX-371 | Participants with TEAEs | 22 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: Placebo | Participants with TEAEs | 23 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: VX-371 in HS | Participants with Serious TEAEs | 1 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: HS | Participants with Serious TEAEs | 1 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: VX-371 | Participants with Serious TEAEs | 1 | Participants | |
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part A: Placebo | Participants with Serious TEAEs | 1 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: VX-371 in HS + IVA | Participants with TEAEs | 5 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: HS + IVA | Participants with TEAEs | 17 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: VX-371 + IVA | Participants with TEAEs | 5 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: Placebo + IVA | Participants with TEAEs | 9 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: VX-371 in HS + IVA | Participants with Serious TEAEs | 0 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: HS + IVA | Participants with Serious TEAEs | 0 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: VX-371 + IVA | Participants with Serious TEAEs | 1 | Participants | |
| Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Part B: Placebo + IVA | Participants with Serious TEAEs | 0 | Participants | |
| Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | Part A: VX-371 in HS | 0.989 | Standard Error 0.7097 | Percentage of predicted FEV1 | |
| Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | Part A: HS | -0.531 | Standard Error 0.7202 | Percentage of predicted FEV1 | |
| Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | Part A: VX-371 | -0.491 | Standard Error 1.0736 | Percentage of predicted FEV1 | |
| Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | Part A: Placebo | -1.329 | Standard Error 1.0730 | Percentage of predicted FEV1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02871778/results